acetic acid lauric acid-anhydride | 126882-41-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: acetic acid lauric acid-anhydride
• 英文别名: Essigsaeure-laurinsaeure-anhydrid；Acetyl dodecanoate
• CAS: 126882-41-5
• 化学式: C₁₄H₂₆O₃
• 分子量: 242.359
• InChiKey: BRXPETQWSNQLQV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  17
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  乙烯酮 、 月桂酸 在 乙醚 作用下， 生成 acetic acid lauric acid-anhydride
  参考文献：
  名称：

  Acetylation of Monocarboxylic Acids with Ketene

  摘要：

  DOI：

  10.1021/ja01620a060

文献信息

• personal care products incorporating cellulosic fatty acid esters
  申请人：Shelton Charles Michael

  公开号：US20060062749A1

  公开（公告）日：2006-03-23

  A personal care product composition containing a long chain fatty acid cellulose ester (LCCE) having a degree of substitution greater than about 1.0 of an ester substituent or residue from fatty acids having from 6 to 18 carbon atoms wherein the LCCE is soluble in at least one cosmetically acceptable solvent selected from the group consisting of hydrocarbons, alkyl esters, fats and oils, fatty acids, fatty alcohols, and silicone oils.

  一种个人护理产品组合物，包含具有取代度大约大于1.0的长链脂肪酸纤维素酯（LCCE），该酯基或残基来自具有6至18个碳原子的脂肪酸，其中LCCE可溶于至少一种从烃、烷基酯、脂肪和油脂、脂肪酸、脂肪醇和硅油等成分中选择的至少一种化妆品可接受的溶剂。
• [EN] METHODS OF TREATING CANCERS, IMMUNE AND AUTOIMMUNE DISEASES, AND INFLAMMATORY DISEASES BASED ON BTK OCCUPANCY AND BTK RESYNTHESIS RATE<br/>[FR] PROCÉDÉS DE TRAITEMENT DE CANCERS, MALADIES IMMUNITAIRES ET AUTO-IMMUNES, ET MALADIES INFLAMMATOIRES BASÉS SUR L'OCCUPATION DE BTK ET LE TAUX DE RESYNTHÈSE DE BTK
  申请人：ACERTA PHARMA BV

  公开号：WO2016020901A1

  公开（公告）日：2016-02-11

  In an embodiment, therapeutic methods and use of a Bruton's Tyrosine Kinase (BTK) inhibitor for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, and for transplantation prophylaxis, based on BTK occupancies and/or BTK resynthesis rates for B cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described. In an embodiment, dosing regimens for a BTK inhibitor for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, and for transplantation prophylaxis, based on BTK occupancies and/or BTK resynthesis rates for B cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described.

  在一种实施方式中，描述了治疗癌症、炎症、免疫紊乱和自身免疫疾病的治疗方法以及使用布鲁顿氨基酸激酶（BTK）抑制剂进行移植预防，基于B细胞在各种疾病、组织区域（包括骨髓和淋巴结）中的BTK占据率和/或BTK再合成速率。在一种实施方式中，描述了基于B细胞在各种疾病、组织区域（包括骨髓和淋巴结）中的BTK占据率和/或BTK再合成速率的BTK抑制剂的剂量方案，用于治疗癌症、炎症、免疫紊乱和自身免疫疾病，以及用于移植预防。
• ORALLY ADMINISTRABLE MODIFIED-RELEASE PHARMACEUTICAL DOSAGE FORM
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20200030270A1

  公开（公告）日：2020-01-30

  The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.

  本发明涉及口服可改性释放药物剂型，包括氯化钠(3S)-3-(4-氯-3-[(2S,3R)-2-(4-氯苯基)-4,4,4-三氟-3-甲基丁酰]氨基}苯基)-3-环丙基丙酸酯，并涉及制备药物剂型的过程以及它们用于治疗和/或预防疾病的用途，特别是用于治疗和/或预防心脏、肾脏和肺部疾病、中枢神经系统疾病、纤维化和炎症性疾病以及代谢性疾病。
• [EN] CONTINUOUS COMBINATION THERAPY WITH SELECTIVE PROSTAGLANDIN EP4, RECEPTOR AGONISTS AND AN ESTROGEN FOR THE TREATMENT OF CONDITIONS THAT PRESENT WITH LOW BONE MASS<br/>[FR] POLYTHERAPIE CONTINUE AVEC DES AGONISTES SELECTIFS DES RECEPTEURS EP4 DE LA PROSTAGLANDINE ET UN OESTROGENE POUR LE TRAITEMENT DE PATHOLOGIES SE MANIFESTANT PAR UNE FAIBLE MASSE OSSEUSE
  申请人：PFIZER PROD INC

  公开号：WO2005060946A1

  公开（公告）日：2005-07-07

  This invention is directed to methods for treating conditions which present with low bone mass in a patient in need thereof using continuous combination therapy with a synergistically effective combination of an EP4 receptor selective agonist or a pharmaceutically acceptable salt thereof, such as 5-(3-2S-[3R-hydroxy­4-(3-trifluoromethyl-phenyl)-butyl]-5-oxo-pyrrolid in-1-yl}-propyl)-thiophene-2­carboxylic acid or a pharmaceutically acceptable salt thereof; and an estrogen or a pharmaceutically effective salt thereof. The present methods are useful for treating conditions that present with low bone mass including osteoporosis, osteotomy, osteoporotic fracture, childhood idiopathic bone loss, periodontitis and low bone mass and for enhancing bone healing following facial reconstruction, maxillary reconstruction or mandibular reconstruction, inducing vertebral synostosis, enhancing long bone extension, enhancing the healing rate of a bone graft or a long bone fracture or enhancing prosthetic ingrowth in a patient in need thereof.

  本发明涉及使用具有协同作用的EP4受体选择性激动剂或其药学上可接受的盐（例如5-（3-2S-[3R-羟基-4-（3-三氟甲基苯基）-丁基]-5-氧代吡咯烷-1-基}-丙基）-噻吩-2-羧酸或其药学上可接受的盐）和雌激素或其药学上有效的盐的连续联合疗法，用于治疗患有低骨密度的患者的疾病。本方法适用于治疗低骨密度症状，包括骨质疏松症、骨切开术、骨质疏松性骨折、儿童特发性骨质流失、牙周炎和低骨质量，以及增强面部重建、上颌重建或下颌重建后的骨愈合，诱导椎体融合，增强长骨延长，增强骨移植或长骨骨折的愈合速度或增强患者的假体生长。
• MODIFIED RELEASE FORMULATIONS OF A BUPROPION SALT
  申请人：OBEREGGER Werner

  公开号：US20080038348A1

  公开（公告）日：2008-02-14

  The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.

  本发明涉及药物组合物、配方和药物，包括一种丁螺环酮盐，特别是包括有效量的丁螺环酮氢溴酸盐的缓释片剂，以及使用丁螺环酮盐来制备治疗疾病的药物。